Goldman Sachs Holds Steady on Pfizer Amid Mounting Margin Pressures and Patent Cliff Concerns
Goldman Sachs maintains a Neutral stance on Pfizer (PFE) with a $26 price target, as the pharmaceutical giant navigates significant margin pressures from looming patent expiries and a constrained business development budget.